Invention Grant
US08569276B2 Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
有权
19-去甲孕酮I：17-α-取代-11-β-取代-4-芳基和21-取代的19-去甲孕酮二酮作为新的抗孕剂的结构修饰
- Patent Title: Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
- Patent Title (中): 19-去甲孕酮I：17-α-取代-11-β-取代-4-芳基和21-取代的19-去甲孕酮二酮作为新的抗孕剂的结构修饰
-
Application No.: US11069817Application Date: 2005-02-28
-
Publication No.: US08569276B2Publication Date: 2013-10-29
- Inventor: Hyun K. Kim , Richard P. Blye , Pemmaraju N. Rao , James W. Cessac , Carmie K. Acosta
- Applicant: Hyun K. Kim , Richard P. Blye , Pemmaraju N. Rao , James W. Cessac , Carmie K. Acosta
- Applicant Address: US DC Washington
- Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US DC Washington
- Agency: Leydig, Voit & Mayer, Ltd.
- Main IPC: A61K31/56
- IPC: A61K31/56 ; C07J5/00
Abstract:
The present invention relates, inter alia, to compounds having the general formula: in which R1, R2, R3, R4 and X are as defined by the present specification. In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception.
Public/Granted literature
Information query
